We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App





Adaptable Lateral Flow Test Reader Being Promoted at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: The ADxLR5 lateral flow assay reader (Photo courtesy of Abingdon Health).
Image: The ADxLR5 lateral flow assay reader (Photo courtesy of Abingdon Health).
A lateral flow test reader for either existing assays or for user-designed tests will be highlighted at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Abingdon Health (York, United Kingdom) will be highlighting its [U.S.] Food and Drug Administration registered and CE marked lateral flow reader, the ADxLR5, in Booth 3838 at the Philadelphia meeting.

The next generation ADxLR5 Lateral Flow Assay reader incorporates a 10.1-inch touch screen with graphical user interface and icon driven software. The sample draw with interchangeable inserts allows for the reading of a wide range of devices and assays. Connectivity is via two USB ports, Ethernet connection, or WiFi.

The ADxLR5 reader complements Abingdon Health's Seralite – FLC (free light chain) rapid test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories with results available in about 10 minutes rather than days or weeks.

In addition, The ADxLR5 is fully customizable for user-designed fluorescence or colorimetric tests and is compatible with most formats of cassettes and test strips. The instrument includes touchscreen PC software to augment flexible test system development.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Abingdon Health
Gold Supplier
COVID-19 Real Time RT-PCR Kit
respiraScreen 1
New
Gold Supplier
Immunofluorescence Incubator
RaFIA Immunofluorescence Incubator
New
Silver Supplier
3-Part Diff Hematology Analyzer
Abacus Junior 30
New
Microplate Reader
VANTAstar

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.